Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers

Oncology (Switzerland)

Volumn 54, Issue 4, 1997, Pages 275-280

  Hsu, Chih Hung ^a,b   Yeh, Kun Huei ^a,b   Chen, Li Tzong ^c,d   Liu, Jacqueline Ming ^c   Jan, Chang Ming ^d   Lin, Jaw Town ^a   Chen, Yao Chang ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

5 Fluorouracil and leucovorin; Gastric cancer; High dose

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG INFUSION; FEMALE; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0030964196     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227702     Document Type: Article

References (23)

1. Health and Vital Statistics. Department of Health, the Executive Yuan, ROC, 1994.
2. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995:333:32-41.
3. Cunningham D, Hole D, Taggart DJ. Soukop M, Carter DC. McArdle CS: An evaluation of the prognostic factors in gastric cancer: The effects of chemotherapy on survival. Br J Surg 1987;74:715-721.
4. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Ilcinicke A, Meyer J, Bunte H: Chemotherapy of gastric cancer. Cancer Treat Rev 1988;15:257-277.
5. Wilke H, Preusser P, Fink U, Achterrath W, Meyer H-J, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, Köhne-Wömpner CH, Har-strick A, Schmoll HJ: New development in the treatment of gastric carcinoma. Semin Oncol 1990; 17/1 (suppl 2):61-70.
6. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer H-J, Buente H: Phase II study with combination of etoposidc, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989:7:1310-1317.
7. Rougier Ph, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Olivcrira J, Bognel C, lesser Ph, Yehou M, Elias D, Cvitkovic E, Armand JP, Droz JP: Efficacy of combined 5-fluoroura-cil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur JCancer 1994;30A: 1263-1269.
8. Kelson D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M: FAMTX versus etoposidc, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-548.
9. Cullman SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF, for the North Central Cancer Treatment Group: A comparison of chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985; 253:2061-2067.
10. Cullman SA, Moertel CG, Wicnand HS, O'Connel MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK, for the North Central Cancer Treatment Group: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994:12:412-416.
11. Kin NK, Park YS, Heo DS, Suh C, Kim SY, Pari KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CL Bang YJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-3818.
12. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, Richman S, Lepaspi A, Wald-man S, Morrell L, Fcun L, Savaraj N, Livingstone A: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leu-covorin in colorectal carcinoma. J Clin Oncol 1991;9:625-630.
13. Yeh KH, Cheng AL: An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leu-covorin (letter). J Clin Oncol 1994; 12:875-876.
14. Yeh KH, Cheng AL, Chen YC, Lin MT, Hong RL, Hsieh CY: Unusual neurotoxicity during 24-hour infusion of high-dose 5-fluorouracil and folinic acid in malnourished hypotriglycer-idemic cancer patients. Proc Am Soc Clin Oncol 1995:14:167.
15. Yeh KH, Cheng AL: High-dose 5-fluorouracil infusion therapy is associated with hyperammonemia, lactic acidosis, and encephalopathy. Br J Cancer, in press.
16. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5: 649-655.
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958:53:457-481.
18. Bartolomeo MD, Bajetta E, Braud F, Bochic-chio AM, Gebbia V, Bozzetti F, Doci R, Bon-fanti G, Cozzaglio L: Phase II study of the eto-poside, lcucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology 1995;52:41-44.
19. Wils J: The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.
20. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vanden-bulcke JM, Misset JL, Schwarzenberg L, Four-tillan JB, Gaget H, Mat he G: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-696.
21. Berenberg JL, Tangen C, Macdonald JS, Hutchins LF, Natale RB, Oishi N, Guy JT, Fleming TR: Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group Study. Cancer 1995;76:715-719.
22. Houghton JA, Williams LG, DcGraaf SSN, Cheshire PJ, Rodman JH. Maneval DC, Warner IW, Jadaud P, Houghton PJ: Relationship between dose rate of (6RS) lcucovorin administration, plasma concentrations of reduced folates and pools of 5, 10-methylenc-tctrahydro-folates and tctrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 1990: 50:3493-3502.
23. Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyridamidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50:197-201.